KNSA Kiniksa Pharmaceuticals International, plc

CIK 0001730430 46 ready 8-Ks latest July 28, 2026, 7:33 AM ET RSS · JSON

Activity: QUIET 0 filings / 30d vs 1 baseline Risk accumulating: repeated leadership change (2)

Ready 8-Ks 46

Latest filing July 28, 2026, 7:33 AM ET

Top materiality 0.90

Event mix earnings ×19 · other_material ×19 · leadership ×4

Sentiment 25 pos · 0 neg · 21 neu

Latest earnings reported 2026-Q1

Executive change recent →

SHENANIGAN SCORE 1 / 7 see the board

Recent 8-K filings for KNSA

Highest-materiality recent filing

Kiniksa Reports Q1 2026 ARCALYST Revenue of $214.3M, Raises 2026 Guidance to $930-$945M

April 28, 2026, 7:59 PM ET earnings materiality 0.90 positive item 2.02 item 9.01 ◈ Earnings Releases

ARCALYST Q1 2026 net product revenue $214.3 million, representing 56% year-over-year growth.
2026 ARCALYST net product revenue guidance raised to $930-$945 million from prior $900-$920 million.

Read filing →

July 28, 2026, 7:33 AM ET earnings materiality 0.75 positive item 2.02 item 9.01

Kiniksa Q2 ARCALYST revenue $243.6M (+55% YoY); raises FY2026 guidance to $980-995M

ARCALYST net product revenue $243.6M in Q2 2026, ~55% YoY growth; ~21% of 14,000 multiple-recurrence patients on therapy.
May 29, 2026, 4:35 PM ET other materiality 0.15 neutral item 5.07 ◈ Shareholder Votes ×8

Kiniksa shareholders re-elect all three Class II directors and approve all eight proposals at 2026 annual meeting

Stephen R. Biggar re-elected with 37.5M for, 12.0M against; G. Bradley Cole and Barry D. Quart each received ~48.3M for.
May 26, 2026, 4:55 PM ET other material materiality 0.60 neutral item 1.01 item 9.01 ◈ Material Agreements

Kiniksa caps Baker Bros. voting power at 49.9% by waiving conversion rights

Baker Bros. entities hold 12.78M A1 and 16.06M B1 shares; they waive conversion into A/B shares if ownership exceeds 49.9% voting rights.
May 1, 2026, 7:59 PM ET leadership materiality 0.35 neutral item 5.02 ◈ executive_change ×2

Kiniksa CSO Eben Tessari resigns, signs consulting deal at $450/hr

Eben Tessari resigned as Chief Strategy Officer effective May 15, 2026, to take another life-sciences executive role.
April 28, 2026, 7:59 PM ET earnings materiality 0.90 positive item 2.02 item 9.01 ◈ Earnings Releases

Kiniksa Reports Q1 2026 ARCALYST Revenue of $214.3M, Raises 2026 Guidance to $930-$945M

ARCALYST Q1 2026 net product revenue $214.3 million, representing 56% year-over-year growth.
February 24, 2026, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

Kiniksa reports Q4/FY 2025 net income; ARCALYST revenue up 62% to $677.6M; guides 2026 $900-920M

ARCALYST net product revenue $202.1M Q4, $677.6M FY 2025 (+62% YoY); gross-to-net improved to 8.4%.
January 14, 2026, 6:59 PM ET leadership materiality 0.60 neutral item 5.02

Kiniksa appoints Ross Moat as COO and Eben Tessari as Chief Strategy Officer

Ross Moat promoted to COO effective Jan 10, 2026; will oversee commercial and functional operations.
January 12, 2026, 6:59 PM ET other material materiality 0.75 positive item 2.02 item 9.01

Kiniksa 2025 ARCALYST revenue $677.5M (+62% YoY), guides 2026 to $900-920M

ARCALYST net product revenue $677.5M in 2025, up ~62% YoY from $417.0M in 2024.
October 28, 2025, 7:59 PM ET earnings materiality 0.80 positive item 2.02 item 9.01

Kiniksa Q3 ARCALYST revenue $180.9M (+61% YoY); raises 2025 guidance to $670-675M

Net income $18.4M (vs loss $12.7M); cash $352.1M, no debt.
September 3, 2025, 7:59 PM ET other material materiality 0.10 neutral item 7.01 item 9.01

Kiniksa posts September 2025 investor presentation, no material new information disclosed

Investor presentation posted on investors.kiniksa.com on September 3, 2025.
July 29, 2025, 7:59 PM ET earnings materiality 0.80 positive item 2.02 item 9.01

Kiniksa Q2 ARCALYST revenue $156.8M (+52% YoY); raises 2025 guidance to $625-640M

ARCALYST net product revenue $156.8M in Q2 2025, up 52% from $103.4M in Q2 2024 (excl. $5.2M license revenue).
June 5, 2025, 7:59 PM ET other material materiality 0.40 neutral item 7.01 item 9.01

Kiniksa details Phase 2/3 trial design for KPL-387 in recurrent pericarditis; initiation mid-2025

Phase 2/3 trial: dose-focusing portion enrolls up to ~80 patients; pivotal portion up to ~85.
June 3, 2025, 7:59 PM ET other material materiality 0.15 neutral item 5.07

Kiniksa shareholders elect all director nominees and approve all 13 proposals at annual meeting

All 10 director nominees elected; Stephen R. Biggar received 15.3M against votes, Felix J. Baker 12.3M against.
April 29, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

Kiniksa Q1 2025 ARCALYST revenue $137.8M (+75% YoY); guides FY 2025 to $590-605M

ARCALYST net product revenue $137.8M in Q1 2025, up 75% YoY; net income $8.5M vs loss of $17.7M in Q1 2024.
April 23, 2025, 7:59 PM ET other material materiality 0.55 neutral item 5.02 item 9.01

Kiniksa approves KPL-387 LTIP for execs, grants PSUs and options tied to BLA submission and FDA approval

Compensation Committee approved KPL-387 Long-Term Incentive Plan for executive officers, linked to BLA submission (Milestone 1) and FDA approval (Milestone 2) for recurrent pericarditis treatment.
February 25, 2025, 6:59 PM ET earnings materiality 0.75 neutral item 1.02 item 2.02 item 2.05 item 9.01 ◈ Restructurings & Charges

Kiniksa Q4 ARCALYST rev $122.5M ($417M FY); guides 2025 $560-580M; discontinues mavrilimumab & abiprubart

ARCALYST Q4 net product revenue $122.5M; full year $417.0M (79% YoY growth).
January 13, 2025, 6:59 PM ET other material materiality 0.80 positive item 2.02 item 9.01

Kiniksa reports 2024 ARCALYST net product revenue $416.4M (+79% YoY); guides 2025 to $560-580M

ARCALYST net product revenue: Q4 2024 $121.9M, FY 2024 $416.4M (unaudited), ~79% YoY growth.
October 29, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

Kiniksa Q3 ARCALYST revenue $112.2M (+73% YoY); FY guidance raised to $410-420M

ARCALYST Q3 net product revenue $112.2M, up 73% YoY; FY 2024 guidance raised to $410-420M from $405-415M.
October 7, 2024, 7:59 PM ET leadership materiality 0.30 neutral item 5.02 ◈ executive_change

Kiniksa appoints M. Cantey Boyd to Board, increasing size to 10 directors

Board size increased from 9 to 10; Boyd appointed as Class III director.
July 23, 2024, 7:59 PM ET earnings materiality 0.80 positive item 2.02 item 9.01

Kiniksa Q2 ARCALYST revenue $103.4M (+90% YoY); 2024 guidance raised to $405-415M

ARCALYST net product revenue $103.4M in Q2 2024, up 90% YoY; ~11% of target 14,000 patients on therapy.
June 28, 2024, 7:59 PM ET other material materiality 0.70 neutral item 1.01 item 3.01 item 3.02 item 3.03 item 5.03 item 5.02 item 8.01 item 9.01

Kiniksa completes redomiciliation from Bermuda to UK, shares trade on Nasdaq under same symbol KNSA

Effective June 27, 2024, Kiniksa redomiciled to UK via Bermuda court-approved scheme of arrangement.
June 25, 2024, 7:59 PM ET other material materiality 0.60 neutral item 1.01 item 9.01

Kiniksa signs manufacturing agreement with Samsung Biologics for ARCALYST

Wholly-owned subsidiary entered MSA and PSA with Samsung Biologics for ARCALYST (rilonacept) drug substance.
June 14, 2024, 7:59 PM ET other material materiality 0.50 neutral item 8.01

Kiniksa gets Bermuda court sanction for redomiciliation to UK, effective ~June 27

Bermuda Supreme Court sanctioned the scheme of arrangement on June 14, 2024.
June 5, 2024, 7:59 PM ET other material materiality 0.15 neutral item 5.07

Kiniksa shareholders approve redomiciliation scheme; court sanction hearing set for June 14

Scheme of arrangement approved by 61,460,949 votes for, 501,355 against, 274,060 abstained.
April 23, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01 ◈ Earnings Releases

Kiniksa Q1 ARCALYST revenue $78.9M (+85% YoY); raises 2024 guidance to $370-390M

ARCALYST net product revenue $78.9M in Q1 2024, up 85% YoY; total revenue $79.9M vs $48.3M in Q1 2023.
April 2, 2024, 7:59 PM ET other material materiality 0.55 positive item 7.01 item 9.01

Kiniksa plans Phase 2b trial of abiprubart in Sjogren's Disease; reports RA Cohort 4 data

Phase 2b trial in Sjogren's Disease to initiate 2H 2024; 201 patients, 24-week placebo-controlled, primary endpoint ESSDAI.
March 29, 2024, 7:59 PM ET other material materiality 0.70 neutral item 8.01 item 9.01

Kiniksa proposes redomicile from Bermuda to UK via scheme of arrangement; expects completion H2 2024

Proposes to change principal holding company incorporation from Bermuda to the UK by scheme of arrangement.
February 28, 2024, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01 ◈ Earnings Releases ×2

Kiniksa Q4 ARCALYST rev $71.2M (+15% YoY); FY2024 guidance $360-380M

ARCALYST net product revenue $71.2M Q4 2023, $233.2M full-year 2023; ~9% of target 14,000 patients active on therapy.
January 4, 2024, 6:59 PM ET other material materiality 0.80 positive item 2.02 item 7.01 item 9.01 ◈ Earnings Releases

Kiniksa reports ARCALYST 2023 net revenue $233.1M; abiprubart Phase 2 meets primary endpoint

ARCALYST 2023 net product revenue $233.1M, up ~90% YoY; Q4 2023 revenue $71.2M.
October 31, 2023, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01 ◈ Earnings Releases

Kiniksa Q3 ARCALYST revenue $64.8M (+94% YoY); tracking to high end of FY guidance

ARCALYST net product revenue $64.8M, ~94% YoY growth; total revenue $67.0M (incl. $2.2M license).
July 25, 2023, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01 ◈ Earnings Releases

Kiniksa Q2 ARCALYST revenue $54.5M; raises FY2023 guidance to $220-230M

Q2 total revenue $71.5M (vs $27.0M YoY), ARCALYST net product revenue $54.5M (vs $27.0M YoY).
June 7, 2023, 7:59 PM ET other material materiality 0.15 neutral item 5.07 ◈ Shareholder Votes ×3

Kiniksa annual meeting elects three directors, ratifies auditor, approves say-on-pay

Stephen R. Biggar, G. Bradley Cole, and Barry D. Quart elected as Class II directors with majority vote.
May 2, 2023, 7:59 PM ET earnings materiality 0.70 positive item 2.02 item 9.01 ◈ Earnings Releases

Kiniksa raises ARCALYST FY2023 guidance; Q1 revenue $48.3M, net loss narrows

ARCALYST Q1 net product revenue $42.7M; FY2023 guidance raised to $200-215M (~69% YoY growth at midpoint).
March 13, 2023, 7:59 PM ET regulatory materiality 0.55 positive item 7.01

Kiniksa reveals no exposure to Silicon Valley Bank; no deposits or securities held

Kiniksa confirmed it did not hold cash deposits or securities with SVB.
February 28, 2023, 6:59 PM ET earnings materiality 0.80 positive item 2.02 item 9.01 ◈ Earnings Releases

Kiniksa reports Q4 net income $4.5M vs loss; ARCALYST revenue $122.5M in FY2022

ARCALYST net product revenue $39.9M in Q4, $122.5M full-year 2022; FY2023 guidance $190-205M.
January 9, 2023, 6:59 PM ET other material materiality 0.70 positive item 2.02 item 9.01 ◈ Earnings Releases ×2

Kiniksa reports preliminary ARCALYST revenue of $122.5M for FY2022; cash $190.4M

ARCALYST net revenue Q4 2022 $39.9M, full-year $122.5M (unaudited).
November 1, 2022, 7:59 PM ET earnings materiality 0.80 positive item 2.02 item 9.01 ◈ Earnings Releases

Kiniksa Q3 ARCALYST rev $33.4M, total rev $99.1M, net income $224.1M on tax benefit

ARCALYST net revenue $33.4M in Q3 2022; full-year guidance reaffirmed at $115-130M.
August 3, 2022, 7:59 PM ET M&A materiality 0.85 positive item 1.01 item 2.02 item 7.01 item 9.01

Kiniksa licenses vixarelimab to Genentech for $100M upfront; Q2 ARCALYST rev $27M

Genentech gets worldwide rights to vixarelimab; Kiniksa receives $100M upfront/near-term and up to $600M in milestones plus tiered royalties.
June 30, 2022, 7:59 PM ET other material materiality 0.15 neutral item 5.07

Kiniksa shareholders elect three Class I directors, ratify PwC, approve say-on-pay

Sanj K. Patel, Thomas R. Malley, Richard S. Levy elected as Class I directors with 33.3M, 31.5M, 34.4M votes for respectively.
May 3, 2022, 7:59 PM ET earnings materiality 0.65 positive item 2.02 item 9.01

Kiniksa Q1 2022 ARCALYST net revenue $22.2M; net loss narrows to $25.2M; FY2022 guidance $115-130M

ARCALYST net revenue $22.2M in Q1 2022 versus $0 in Q1 2021; total revenue $32.2M including $10M collaboration revenue.
February 22, 2022, 6:59 PM ET M&A materiality 0.75 positive item 1.01 item 2.02 item 7.01 item 9.01

Kiniksa and Huadong Medicine $22M upfront Asia Pacific deal; ARCALYST FY2022 rev guidance $115-130M

Upfront $22M from Huadong; up to $640M milestones + low-teens to low-twenties royalties on net sales for ARCALYST and mavrilimumab in Asia Pacific (ex-Japan).
January 10, 2022, 6:59 PM ET other material materiality 0.70 neutral item 2.02 item 9.01

Kiniksa reports ~$182M year-end cash sufficient into 2024; mavrilimumab Phase 3 fails; pipeline updates

Preliminary year-end 2021 cash, cash equivalents and short-term investments of ~$182M (unaudited), expected to fund operations into 2024.
January 3, 2022, 6:59 PM ET leadership materiality 0.30 neutral item 5.02 item 9.01 ◈ executive_change

Kiniksa appoints Eben Tessari as SVP, Chief Operating Officer

Eben Tessari promoted to COO effective Jan 3, 2022; previously SVP Chief Business Officer.
November 1, 2021, 7:59 PM ET earnings materiality 0.65 neutral item 2.02 item 9.01

Kiniksa reports Q3 ARCALYST net revenue of $12.1M; net loss narrows to $30.5M

ARCALYST net revenue $12.1M in Q3 2021; Q4 2021 revenue guided to $16-17M.
August 3, 2021, 7:59 PM ET earnings materiality 0.70 positive item 2.02 item 9.01

Kiniksa posts Q2 ARCALYST revenue of $7.7M; net loss $41.6M; guides Q3 rev $9-10M

ARCALYST net revenue $7.7M in first quarter of sales (April 1 launch); >100 physicians prescribed in Q2.
July 6, 2021, 7:59 PM ET other material materiality 0.15 neutral item 5.07

Kiniksa shareholders elect directors, ratify auditor, approve exec pay, adopt annual say-on-pay vote

Felix J. Baker, Tracey L. McCain, Kimberly J. Popovits elected as Class III directors with ~32.8M, 35.9M, 35.8M votes for, respectively.

Executive changes

Appointed

Eben Tessari

special advisor to the Company's Science and Research Committee

KNSA · Kiniksa Pharmaceuticals International, plc

Effective: 2026-05-15
Filed: May 1, 2026, 7:59 PM ET

Pursuant to a Consulting Agreement (the "Consulting Agreement") between Mr. Tessari and the Company, which will be effective as of May 15, 2026, Mr. Tessari will: (i) provide services to the Company related to strategic and operational matters and (ii) serve as a special advisor to the Company's Science and Research Committee (together, the "Services").

Departed

Eben Tessari

Chief Strategy Officer

KNSA · Kiniksa Pharmaceuticals International, plc

Effective: 2026-05-15
Filed: May 1, 2026, 7:59 PM ET

On April 30, 2026, Eben Tessari informed Kiniksa Pharmaceuticals International, plc (the "Company") of his decision to resign as Chief Strategy Officer of the Company to pursue another executive position within the life sciences industry.

Appointed

M. Cantey Boyd

Director

KNSA · Kiniksa Pharmaceuticals International, plc

Effective: 2024-10-04
Filed: October 7, 2024, 7:59 PM ET

the appointment of M. Cantey Boyd, age 44, to the Board to fill the vacancy created thereby

Role change

Eben Tessari

SVP, Chief Operating Officer

KNSA · Kiniksa Pharmaceuticals International, plc

Effective: 2022-01-03
Filed: January 3, 2022, 6:59 PM ET

Effective January 3, 2022, the Board of Directors (the “Board”) of Kiniksa Pharmaceuticals, Ltd. (the “Company”) appointed Eben Tessari as the Company’s SVP, Chief Operating Officer and principal operating officer.

Earnings & guidance

2026-Q1 EPS reported $0.27 filing →

Materiality & sentiment trend

Max materiality 0.90 · Median 0.70 · Most common event earnings

25 positive 0 negative 21 neutral

source · KNSA on sec.gov